4.3 Article

Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking N-acetyl-cysteine versus placebo

Journal

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
Volume 47, Issue 4, Pages 347-354

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/0004867412474074

Keywords

Anterior cingulate cortex; major depressive disorder; N-acetyl-cysteine; proton magnetic spectroscopy

Categories

Funding

  1. National Health and Medical Research Council (NHMRC) [APP628395]
  2. NHMRC [510135]
  3. Australian Rotary Health
  4. AstraZeneca
  5. Eli Lilly
  6. Organon
  7. Pfizer
  8. Servier
  9. Wyeth
  10. Medical Benefits Fund of Australia
  11. Bristol-Myers Squibb
  12. GlaxoSmithKline
  13. Novartis
  14. Mayne Pharma
  15. Brain and Behavior Foundation
  16. Simons Autism Foundation
  17. Stanley Medical Research Institute
  18. Lilly
  19. NHMRC
  20. ASBD/Servier grant
  21. Beyond Blue
  22. ARHRF
  23. Simons Foundation
  24. Geelong MRF

Ask authors/readers for more resources

Background: Increased oxidative stress is thought to contribute to the pathophysiology of major depressive disorder (MDD), which is in part due to diminished levels of glutathione, the primary anti-oxidant of the brain. Oral administration of N-acetyl-cysteine (NAC) replenishes glutathione and has therefore been shown to reduce depressive symptoms. Proton magnetic spectroscopy (H-1-MRS) that allows quantification of brain metabolites pertinent to both MDD and oxidative biology may provide some novel insights into the neurobiological effects of NAC, and in particular metabolite concentrations within the anterior cingulate cortex (ACC) are likely to be important given the key role of this region in the regulation of affect. Objective: The aim of this study was to determine whether the metabolite profile of the ACC in MDD patients predicts treatment with adjunctive NAC versus placebo. Methods: This study was nested within a multicentre, randomized, double-blind, placebo-controlled study of MDD participants treated with adjunctive NAC. Participants (n = 76) from one site completed the spectroscopy component at the end of treatment (12 weeks). Spectra from a single-voxel in the ACC were acquired and absolute concentrations of glutamate (Glu), glutamate-glutamine (Glx), N-acetyl-aspartate (NAA) and myo-inositol (mI) were obtained. Binary logistic regression analysis was performed to determine whether metabolite profiles could predict NAC versus placebo group membership. Results: When predicting group outcome (NAC or placebo), Glx, NAA and mI were a significant model, and had 75% accuracy, while controlling for depression severity and sex. However, the Glu, NAA and mI profile was only predictive at a trend level, with 68.3% accuracy. For both models, the log of the odds of a participant being in the NAC group was positively related to NAA, Glx and Glu levels and negatively related to mI levels. Conclusion: The finding of higher Glx and NAA levels being predictive of the NAC group provides preliminary support for the putative anti-oxidative role of NAC in MDD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available